Leitch H A, Buskard N, Levy J G
Department of Microbiology, University of British Columbia, Vancouver, Canada.
Leukemia. 1993 Sep;7(9):1394-401.
CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopoiesis by normal progenitor cells in vitro. This activity is associated with material which was further purified from CAMAL preparations, and which migrates at 30-35 kDa by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). We now report that material from CAMAL preparations highly enriched for this 30-35 kDa material is stimulatory to in vitro colony formation by progenitor cells from patients with chronic myelogenous leukemia (CML). This stimulatory effect on CML colony formation was observed to be consistent. Colony formation was stimulated in a biphasic fashion; enhancement was seen at low (1 to 10 ng/ml) and high (100 to 200 ng/ml) concentrations of P30-35 CAMAL, but enhancement was reduced or absent at an intermediate concentration of P30-35 CAMAL (10 to 70 ng/ml), and was not observed at P30-35 CAMAL levels above 200 ng/ml, or below 1 ng/ml. The colony types in cultures of CML clinical specimens targetted for enhancement by P30-35 CAMAL were identified. At low concentrations of P30-35 CAMAL primitive colonies were increased, whereas at high concentrations of P30-35 CAMAL, an increase in all colony types was observed. In addition, an increase in the size of some colonies within P30-35 CAMAL-treated cultures was frequently observed. Colony formation by two cell lines derived from the leucocytes of a patient with CML was enhanced by treatment with P30-35 CAMAL in a manner similar to the stimulation observed using primary cells from CML clinical specimens.
髓性急性白血病共同抗原（CAMAL）是本实验室从髓细胞白血病患者的骨髓或外周血细胞中分离出的一种抗原制剂，在免疫过氧化物酶玻片试验中显示可用于诊断这些白血病。已证明CAMAL在体外对正常祖细胞的髓系造血有抑制作用。该活性与从CAMAL制剂中进一步纯化的物质有关，该物质在十二烷基硫酸钠聚丙烯酰胺凝胶电泳（SDS-PAGE）中迁移率为30-35 kDa。我们现在报告，来自CAMAL制剂的高度富集这种30-35 kDa物质的材料对慢性髓性白血病（CML）患者的祖细胞体外集落形成有刺激作用。观察到这种对CML集落形成的刺激作用是一致的。集落形成呈双相刺激；在低浓度（1至10 ng/ml）和高浓度（100至200 ng/ml）的P30-35 CAMAL时可见增强，但在中等浓度的P30-35 CAMAL（10至70 ng/ml）时增强减少或不存在，在P30-35 CAMAL水平高于200 ng/ml或低于1 ng/ml时未观察到增强。确定了P30-35 CAMAL靶向增强的CML临床标本培养物中的集落类型。在低浓度的P30-35 CAMAL时，原始集落增加，而在高浓度的P30-35 CAMAL时，观察到所有集落类型均增加。此外，经常观察到P30-35 CAMAL处理的培养物中一些集落的大小增加。用P30-35 CAMAL处理增强了源自一名CML患者白细胞的两个细胞系的集落形成，其方式类似于使用CML临床标本的原代细胞观察到的刺激。
